Status | Study |
Recruiting |
Study Name: Biomarkers for Early Detection of Ovarian Cancer Using Uterine Lavage Condition: Ovarian Cancer Ovarian Carcinoma Fallopian Tube Cancer Date: 2017-05-03 Interventions: Procedure: Uterine lavage Uter |
Not yet recruiting |
Study Name: VSV-hIFNbeta-NIS in Treating Patients With Stage IV or Recurrent Endometrial Cancer Condition: Endometrial Clear Cell Adenocarcinoma Endometrial Mixed Adenocarcinoma Date: 2017-04-14 Interventions: Procedure: Biopsy Undergo imag |
Recruiting |
Study Name: Cobimetinib and Atezolizumab in Advanced Rare Tumors Condition: Malignant Neoplasms of Digestive Organs Melanoma and Other Malignant Neoplasms of Skin Date: 2017-03-31 Interventions: Drug: Cobimetinib 60 mg by mou |
Not yet recruiting |
Study Name: Olaparib and Hsp90 Inhibitor AT13387 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer Condition: Estrogen Receptor Negative HER2/Neu Negative High Grade Fa Date: 2016-09-12 Interventions: Other: Laboratory Biomarker Analysis |
Recruiting |
Study Name: Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or Uterine Cancer Condition: Breast Carcinoma Endometrial Clear Cell Adenocarcinoma End Date: 2016-08-17 Interventions: Drug: Metformin Hydrochloride |
Recruiting |
Study Name: Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Condition: Fallopian Tube Clear Cell Adenocarcinoma Fallopian Tube Endometrioid Adenocarcinoma Date: 2016-07-29 Interventions: Biological: Bevacizumab Given |
Not yet recruiting |
Study Name: Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Condition: Fallopian Tube Clear Cell Adenocarcinoma Fallopian Tube Endometrioid Adenocarcinoma Date: 2016-07-20 Interventions: Drug: Atezolizumab Given IV |
Recruiting |
Study Name: Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Condition: Acinar Cell Carcinoma Adrenal Cortex Carcinoma Adrenal Gla Date: 2016-07-13 Interventions: Procedure: Biospecimen Collection |
Active, not recruiting |
Study Name: French National Registry of Rare Peritoneal Surface Malignancies Condition: Rare Peritoneal Surface Malignancies Pseudomyxoma Peritonei Date: 2016-06-30 Interventions: Other: Non interventional Data collection |
Not yet recruiting |
Study Name: Proof-of-concept Study of Birinapant in Combination With Platinum Based Chemotherapy in Subjects With High Grade Serous Carcinomas Condition: Advanced Newly Diagnosed or Recurrent High Grade Serous Carcinomas (HGSC) Date: 2016-04-22 Interventions: Drug: Birinapant Birinapant - |